Numbers of colony-forming progenitors in patients with systemic mastocytosis: Potential diagnostic implications and comparison with myeloproliferative disorders

European Journal of Clinical Investigation

Volumn 33, Issue 7, 2003, Pages 611-618

  Jordan, J H ^a,b   Jager E ^a,b   Sperr, W R ^a,b   Schwarzinger, I ^a,b   Fodinger M ^a,b   Fritsche Polanz, R ^a,b   Ohler L ^a,b   Geissler, K ^a,b   Valent, P ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CFU; Classification; Mast cells; Mastocytosis; Myeloproliferative diseases

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; BURST FORMING UNIT E; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING CELL; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MAST CELL LEUKEMIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; STEM CELL; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOSIS;

ADULT; AGED; BONE MARROW CELLS; CELL COUNT; COLONY-FORMING UNITS ASSAY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; STEM CELLS;

EID: 0038127181     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01172.x     Document Type: Article

References (41)

1. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979;3:349-65.
2. Parwaresch MR, Horny H-P, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985;179:439-61.
3. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S-4S.
4. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996;108:385-97.
5. Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577-82.
6. Horan RF, Austen KF. Systemic mastocytosis, retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1993;96:5S-14S.
7. Caplan RM. The natural course of urticaria pigmentosa. Arch Dermatol 1963;87:146-57.
8. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-4.
9. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated haematologic disorder. Proc Natl Acad Sci (USA) 1995;92:10560-4.
10. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-kit mutations in adult-, but not childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behaviour. J Invest Dermatol 1998;111:1227-31.
11. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci (USA) 1999;96:1609-14.
12. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis, a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Clin Immunol 2002;127:110-4.
13. Valent P, Horny H-P, Escribano L, Longley JB, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
14. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott M, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activatig mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000;28:140-7.
15. Yavuz AS, Lipsky PE, Metcalfe DD, Akin C. Evidence for the involvement of a haematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661-5.
16. Jordan JH, Fritsche-Polanz R, Sperr WR, Mitterbauer G, Födinger M, Schernthaner GH et al. A case of smouldering mastocytosis with high mast cell burden, monoclonal myeloid cells, and c-kit mutation Asp-816-Val. Leuk Res 2001;25:627-34.
17. Hauswirth AW, Sperr WR, Ghannadan M, Schernthaner G-H, Jordan J-H, Fritsche-Polanz R et al. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk Res 2002;26:601-6.
18. Tefferi A. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia very, essential thrombocytosis, agnogenic myeloid metaplasia, and chronic myeloid leukaemia. Semin Hematol 1999;36:3-8.
19. Bench AJ, Cross NC, Hundy BJ, Nacheva EP, Green AR. Myeloproliferative disorders. Best Pract Clin Haematol 2001;14:531-51.
20. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders. The new WHO classification. Pathologe 2001;22:429-43.
21. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukaemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977;63:125-30.
22. Fialkow PJ, Jacobson RJ, Singer JW, Sacher RA, McGuffin RW, Neefe JR. Philadelphia chromosome (Ph1)-negative chronic myelogenous leukaemia (CML): a clonal disease with origin in a multipotent stem cell. Blood 1980;56:70-3.
23. Fialkow PJ. Stem cell origin of human myeloid blood cell neoplasms. Verh Dtsch Ges Pathol 1990;74:43-7.
24. Croizat H, Amato D, McLeod DL, Eskinazio D, Axelrad AA. Differences among myeloproliferative disorders in the behaviour of restricted progenitor cells in culture. Blood 1983;62:578-84.
25. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984;57:495-503.
26. Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K. Colony growth characteristics in chronic myelomonocytic leukaemia. Leuk Res 1988;12:373-7.
27. Denburg JA, Richardson M, Telizyn S, Bienenstock J. Basophil/mast cell precursors in human peripheral blood. Blood 1983;61:775-80.
28. Swolin B, Rodjer S, Roupe G. Cytogenetic studies and in vitro colony growth in patients with mastocytosis. Blood 1987;70:1928-32.
29. Swolin B, Rodjer S, al-Obaidy A, Jonell R, Roupe G. A follow up of bone marrow chromosomes and in vitro colony growth in patients with mastocytosis. Acta Derm Venereol 1994;74:163-7.
30. World Health Organization Classification of Tumours. Pathology and Genetics -Tumours of Haematopoietic and Lymphoid Tissues. In: Jaffe ES, Harris NL, Stein H, et al. editors. Lyon: IARC Press; 2001:15-46.
31. Bennett JM, Catovsky D, Daniel MT, Flandrian G, Galton DA, Gralnick HR et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994;87:746-54.
32. Horny H-P, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B et al. Diagnostic value of staining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-40.
33. L. Human Pathol 2001;32:545-52.
34. Öhler L, Födinger M, Köller M, Kollars M, Reiter E, Bohle B et al. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony stimulating factor release. Blood 1997;89:1147-53.
35. Fritsche Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P et al. Mutation analysis of c-kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001;113:357-64.
36. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated haematologic disorders. Cancer 1988;62:965-72.
37. Horny H-P, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990;76:186-93.
38. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestation of systemic mast cell disease, a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991;91:612-24.
39. Sperr WR, Horny H-P, Valent P. Spectrum of associated clonal haematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002;127:140-2.
40. Hagen W, Schwarzmeier J, Walchshofer S, Zojer N, Chott A, Sillaber C et al. A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol 1998;76:167-74.
41. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R et al. Detection of c-kit mutation Asp-816-Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000;53:188-93.